Alan Bernstein

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Alan Bernstein
Born (1947-06-25) June 25, 1947 (age 71)[1]
Alma materUniversity of Toronto
Known forGlobal HIV Vaccine Enterprise[2][3]
Scientific career
InstitutionsCanadian Institute for Advanced Research
Imperial Cancer Research Fund
Mount Sinai Hospital, Toronto
Ontario Cancer Institute
ThesisA Genetic Analysis of the TOL(A,B) Locus of Escherichia Coli K-12 (1972)

Alan Bernstein, OC FRSC (born June 25, 1947)[4] is President and CEO of the Canadian Institute for Advanced Research.[5][6][7][8]


Born in Toronto,[9] Bernstein attended Oakwood Collegiate Institute,[10] and then received his Ph.D. at the University of Toronto.[11][12] Following postdoctoral research in London at the Imperial Cancer Research Fund[3] where he first began working on retroviruses, he returned to Canada in 1974 to join the faculty of the Ontario Cancer Institute. In 1985, he joined the new Samuel Lunenfeld Research Institute at Mount Sinai Hospital as Head of the Division of Molecular and Developmental Biology, and then served as its Director of Research from 1994 – 2000.


Prior to his position at CIFAR, Bernstein was the inaugural executive director of the Global HIV Vaccine Enterprise,[13] an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Bernstein resigned in June 2011.

As Executive Director, Bernstein oversaw the Enterprise Secretariat in implementing activities to support the goals and mission of the Enterprise, including the development of the 2010 Scientific Strategic Plan[2] for HIV vaccine development and facilitating and integrating the activities of the Enterprise partners to ensure their effective implementation of the Enterprise Scientific Strategic Plan.

Prior to leading the Enterprise, Bernstein served as the founding president of the Canadian Institutes of Health Research (CIHR) from 2000 – 2007. During that time, he led a transformation in how health research is organized and funded in Canada and increased Canada's health research budget by 2.5 fold.


Bernstein's research interests have centered on hematopoiesis, cancer and embryonic development. He has authored more than 200 peer-reviewed scientific publications.


For his contributions to science and science in Canada, Bernstein has received the McLaughlin Medal[14] of the Royal Society of Canada, the Robert L. Noble Prize from the National Cancer Institute of Canada, the Genetics Society of Canada Award of Excellence,[15] the 2001 Australian Society of Medical Research Medal, four honorary degrees, the 2007 Medaille du merite from the Institut de Recherche Clinique de Montreal, the 2008 Gairdner Wightman Award and the Order of Canada in 2002. He is a Senior Fellow at Massey College, University of Toronto.[16] In 2015, Bernstein was inducted into the Canadian Medical Hall of Fame.[9]


  1. ^ Bernstein, Alan (1972). A Genetic Analysis of the TOL(A,B) Locus of Escherichia Coli K-12 (PhD thesis). University of Toronto.
  2. ^ a b Berkley, S.; Bertram, K.; Delfraissy, J. F. O.; Draghia-Akli, R.; Fauci, A.; Hallenbeck, C.; Kagame, M. J.; Kim, P.; Mafubelu, D.; Makgoba, M. W.; Piot, P.; Walport, M.; Warren, M.; Yamada, T.; Esparza, J.; Hankins, C.; Johnston, M. I.; Lévy, Y.; Romaris, M.; Ahmed, R.; Bernstein, A. (2010). "The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise". Nature Medicine. 16 (9): 981–989. doi:10.1038/nm0910-981. PMID 20823883.
  3. ^ a b Gewin, V. (2007). "Alan Bernstein, executive director, Global HIV Vaccine Enterprise, Seattle, Washington". Nature. 450 (7167): 316–317. doi:10.1038/nj7167-316a.
  4. ^ Canadian Who's Who Search. Grey House Publishing Canada.
  5. ^ Bernstein, Alan; Rossant, Janet (2013). "Anthony James Pawson". Nature. 501 (7466): 168. doi:10.1038/501168a. PMID 24025833.
  6. ^ Kondro, W. (2007). "Exit interview with Dr. Alan Bernstein". Canadian Medical Association Journal. 177 (8): 844–845. doi:10.1503/cmaj.071276. PMC 1995141. PMID 17923649.
  7. ^ Bernstein, A. (2008). "An interview with Alan Bernstein. Interview by Kristen Jill Kresge. Newspaper Article". IAVI report : newsletter on international AIDS vaccine research. 12 (6): 18–21. PMID 20218020.
  8. ^ Chabot, B.; Stephenson, D. A.; Chapman, V. M.; Besmer, P.; Bernstein, A. (1988). "The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus". Nature. 335 (6185): 88–89. doi:10.1038/335088a0. PMID 2457811.
  9. ^ a b "Dr. Alan Bernstein, OC". Canadian Medical Hall of Fame.
  10. ^ Gasner, Cynthia (May 15, 2008). "Oakwood CI marks 100 years". Canadian Jewish News.
  11. ^ Onodera, K.; Rolfe, B.; Bernstein, A. (1970). "Demonstration of missing membrane proteins in deletion mutants of". Biochemical and Biophysical Research Communications. 39 (5): 969–975. doi:10.1016/0006-291X(70)90419-5. PMID 4912640.
  12. ^ Bernstein, A.; Rolfe, B.; Onodera, K. (1972). "Pleiotropic properties and genetic organization of the tolA,B locus of Escherichia coli K-12". Journal of Bacteriology. 112 (1): 74–83. PMC 251382. PMID 4627928.
  13. ^ Global HIV Vaccine Enterprise.
  14. ^ McLaughlin Medal. Royal Society of Canada.
  15. ^ Genetics Society of Canada Award of Excellence.
  16. ^ McLaughlin Medal winner. Royal Society of Canada.